Risk Analysis from the Burden of Lyme Disease (BOLD) Study
Pathogens · 2026
DOI: 10.3390/pathogens15090961 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens, 2026. Verfasst von Kate Halsby und 12 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Ltd., Tadworth, Surrey KT20 7NS, UK. Hauptthemen laut MEDLINE: Lyme Disease. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Valneva, Pfizer (United Kingdom), Pfizer Inc..
Abstract (Originalsprache)
Lyme borreliosis (LB) is endemic in many European countries. The prospective, epidemiological Burden of Lyme Disease (BOLD) study used unified case definitions to characterise LB burden in Europe. A retrospective case–control study was nested within the BOLD study to better understand LB risk factors. LB patients were evaluated at 14 healthcare practices in high-LB-incidence areas in six European countries: the Czech Republic, Germany, Poland, Slovakia, Slovenia, and Sweden between April 2021 and December 2022. Enrolled cases and age-group-matched controls were interviewed about potential risk factors, and multivariate regression analysis was used to analyse the responses. Patients with LB were more likely than matched controls to live in neighbourhoods with >50% woods, to have a garden that is composed of less than half dense trees, and to have a garden visited by wild animals. Characteristics associated with lower LB risk included being male and not having a bird feeder. The results are suggestive of risk associated with edge-of-the-forest areas, aligning with the previous literature on the increased risk of LB with forest fragmentation. Our findings support the importance of landscape structure and human–environment interactions in shaping LB risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pfizer Ltd., Tadworth, Surrey KT20 7NS, UK.
- Pfizer Corporation Austria GmbH, 1210 Vienna, Austria.
- Department of Infectious Diseases and Neuroinfections, Medical University of Białystok, 15-540 Bialystok, Poland.
- Department of Infectious Diseases, University Medical Centre Ljubljana, 1525 Ljubljana, Slovenia.
- Department of Health, Blekinge Institute of Technology, 371 79 Karlskrona, Sweden.
- Pfizer Inc., Cambridge, MA 02139, USA.
ORCID-Profile: Alexandra Loew-Baselli, Anna Moniuszko-Malinowska, Franc Strle, Johan Sanmartin Berglund, Brad D Gessner, Andreas Pilz, Elizabeth Begier
Förderung
- Valneva
- Pfizer (United Kingdom)
- Pfizer Inc.
- RTI Health Solutions, LLC
Zitieren
APA
Halsby, K., Loew-Baselli, A., Moniuszko-Malinowska, A., Strle, F., Berglund, J. S., Tan, Y., Gessner, B. D., Angulo, F. J., Edwards, J., Pilz, A., Begier, E., Stark, J. H., & On Behalf Of The Bold Study Group (2026). Risk Analysis from the Burden of Lyme Disease (BOLD) Study. Pathogens. https://doi.org/10.3390/pathogens15090961
Vancouver
Halsby K, Loew-Baselli A, Moniuszko-Malinowska A, Strle F, Berglund JS, Tan Y, et al. Risk Analysis from the Burden of Lyme Disease (BOLD) Study. Pathogens. 2026. doi:10.3390/pathogens15090961
BibTeX
@article{Halsby2026,
author = {Halsby, Kate and Loew-Baselli, Alexandra and Moniuszko-Malinowska, Anna and Strle, Franc and Berglund, Johan Sanmartin and Tan, Ye and Gessner, Brad D and Angulo, Frederick J and Edwards, Juanita and Pilz, Andreas and Begier, Elizabeth and Stark, James H and On Behalf Of The Bold Study Group},
title = {Risk Analysis from the Burden of Lyme Disease (BOLD) Study},
journal = {Pathogens},
year = {2026},
doi = {10.3390/pathogens15090961}
}
EUVIMED